Survey finds majority of biotech finance experts expect worsening trends in stock market financing

In a survey carried out in the run-up to the Biotech Finance Summit in Berlin, two-thirds of the finance experts surveyed said they believe the trends in stock market financing will worsen. Yet when it comes to venture capital or corporate venture capital financing, the majority of respondents do not expect any changes – not even changes for the better, despite the successes during the pandemic. “More venture capital” was cited as by far the most important lever for increasing start-up momentum in the biotech sector, but other factors, such as bigger tax incentives for research, more funding programmes, better technology transfer structures and increased seed capital, were also mentioned.

Infographics on the survey’s findings can be found here.